Despite the dire consequences, epinephrine auto-injector devices are only available in 60% of countries, primarily high-income regions. Many countries in South America, Africa, the Middle East, and Asia-Pacific either lack access to these life-saving devices or depend on individual importation.
This lack of accessibility and standardization motivated us to develop Nasdepi®—a dry powder nasal device designed to offer benefits in epinephrine absorption and ease of use, along with a longer shelf life and temperature resistance to enhance accessibility and shipping to underserved regions.
In the US, less than half of Americans at risk are equipped with injectable epinephrine pens. Shockingly, one-third of those who experience an allergic reaction don’t use epinephrine due to fear of needles, uncertainty about how to use it, or expired products.
The stakes are incredibly high; a delay in treatment can mean the difference between life and death. Nasdepi® eliminates these barriers with its compact, user-friendly design that fits in your pocket, ensuring immediate access to treatment and setting a new standard for anaphylaxis care.